Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2005 1
2006 3
2007 1
2008 3
2009 2
2010 3
2011 2
2012 3
2013 3
2014 8
2015 8
2016 6
2017 7
2018 21
2019 19
2020 16
2021 12
Text availability
Article attribute
Article type
Publication date

Search Results

107 results
Results by year

Citations

6 articles found by citation matching

Search results

Filters applied: . Clear all
Page 1
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group. Shapiro J, et al. Among authors: hulshof mccm. Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5. Lancet Oncol. 2015. PMID: 26254683 Clinical Trial.
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar RJAV, Verhagen PCMS, van Andel G. Boevé LMS, et al. Among authors: hulshof mccm. Eur Urol. 2019 Mar;75(3):410-418. doi: 10.1016/j.eururo.2018.09.008. Epub 2018 Sep 25. Eur Urol. 2019. PMID: 30266309 Clinical Trial.
Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study.
Hagens ERC, van Berge Henegouwen MI, van Sandick JW, Cuesta MA, van der Peet DL, Heisterkamp J, Nieuwenhuijzen GAP, Rosman C, Scheepers JJG, Sosef MN, van Hillegersberg R, Lagarde SM, Nilsson M, Räsänen J, Nafteux P, Pattyn P, Hölscher AH, Schröder W, Schneider PM, Mariette C, Castoro C, Bonavina L, Rosati R, de Manzoni G, Mattioli S, Garcia JR, Pera M, Griffin M, Wilkerson P, Chaudry MA, Sgromo B, Tucker O, Cheong E, Moorthy K, Walsh TN, Reynolds J, Tachimori Y, Inoue H, Matsubara H, Kosugi SI, Chen H, Law SYK, Pramesh CS, Puntambekar SP, Murthy S, Linden P, Hofstetter WL, Kuppusamy MK, Shen KR, Darling GE, Sabino FD, Grimminger PP, Meijer SL, Bergman JJGHM, Hulshof MCCM, van Laarhoven HWM, Mearadji B, Bennink RJ, Annema JT, Dijkgraaf MGW, Gisbertz SS. Hagens ERC, et al. Among authors: hulshof mccm. BMC Cancer. 2019 Jul 4;19(1):662. doi: 10.1186/s12885-019-5761-7. BMC Cancer. 2019. PMID: 31272485 Free PMC article.
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB; SANO study group. Noordman BJ, et al. Among authors: hulshof mccm. Lancet Oncol. 2018 Jul;19(7):965-974. doi: 10.1016/S1470-2045(18)30201-8. Epub 2018 Jun 1. Lancet Oncol. 2018. PMID: 29861116
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.
Stroes CI, Schokker S, Creemers A, Molenaar RJ, Hulshof MCCM, van der Woude SO, Bennink RJ, Mathôt RAA, Krishnadath KK, Punt CJA, Verhoeven RHA, van Oijen MGH, Creemers GJ, Nieuwenhuijzen GAP, van der Sangen MJC, Beerepoot LV, Heisterkamp J, Los M, Slingerland M, Cats A, Hospers GAP, Bijlsma MF, van Berge Henegouwen MI, Meijer SL, van Laarhoven HWM. Stroes CI, et al. Among authors: hulshof mccm. J Clin Oncol. 2020 Feb 10;38(5):462-471. doi: 10.1200/JCO.19.01814. Epub 2019 Dec 6. J Clin Oncol. 2020. PMID: 31809243 Free PMC article. Clinical Trial.
Gastro-oesophageal junction: to FLOT or to CROSS?
van den Ende T, Hulshof MCCM, van Berge Henegouwen MI, van Oijen MGH, van Laarhoven HWM. van den Ende T, et al. Among authors: hulshof mccm. Acta Oncol. 2020 Feb;59(2):233-236. doi: 10.1080/0284186X.2019.1698765. Epub 2019 Dec 9. Acta Oncol. 2020. PMID: 31813320 No abstract available.
Thermal dosimetry for bladder hyperthermia treatment. An overview.
Schooneveldt G, Bakker A, Balidemaj E, Chopra R, Crezee J, Geijsen ED, Hartmann J, Hulshof MC, Kok HP, Paulides MM, Sousa-Escandon A, Stauffer PR, Maccarini PF. Schooneveldt G, et al. Among authors: hulshof mc. Int J Hyperthermia. 2016 Jun;32(4):417-33. doi: 10.3109/02656736.2016.1156170. Epub 2016 May 1. Int J Hyperthermia. 2016. PMID: 27132465 Review.
Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.
Steins A, Ebbing EA, Creemers A, van der Zalm AP, Jibodh RA, Waasdorp C, Meijer SL, van Delden OM, Krishnadath KK, Hulshof MCCM, Bennink RJ, Punt CJA, Medema JP, Bijlsma MF, van Laarhoven HWM. Steins A, et al. Among authors: hulshof mccm. Int J Cancer. 2019 Nov 15;145(10):2792-2803. doi: 10.1002/ijc.32364. Epub 2019 May 7. Int J Cancer. 2019. PMID: 31018252 Free PMC article.
Neoadjuvant chemotherapy in oesophageal adenocarcinoma.
van Laarhoven HWM, van Berge Henegouwen MI, Hulshof MCCM. van Laarhoven HWM, et al. Among authors: hulshof mccm. Lancet Oncol. 2017 Nov;18(11):e639. doi: 10.1016/S1470-2045(17)30812-4. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208393 No abstract available.
107 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page